500 related articles for article (PubMed ID: 25889448)
1. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
[TBL] [Abstract][Full Text] [Related]
3. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
4. IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy.
Murakami I; Morimoto A; Oka T; Kuwamoto S; Kato M; Horie Y; Hayashi K; Gogusev J; Jaubert F; Imashuku S; Al-Kadar LA; Takata K; Yoshino T
Virchows Arch; 2013 Feb; 462(2):219-28. PubMed ID: 23269323
[TBL] [Abstract][Full Text] [Related]
5. Merkel cell polyomavirus and Langerhans cell neoplasm.
Murakami I; Wada N; Nakashima J; Iguchi M; Toi M; Hashida Y; Higuchi T; Daibata M; Matsushita M; Iwasaki T; Kuwamoto S; Horie Y; Nagata K; Hayashi K; Oka T; Yoshino T; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F
Cell Commun Signal; 2018 Aug; 16(1):49. PubMed ID: 30134914
[TBL] [Abstract][Full Text] [Related]
6. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
[TBL] [Abstract][Full Text] [Related]
7. Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics.
Murakami I; Oh Y; Morimoto A; Sano H; Kanzaki S; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Hayashi K; Imashuku S; Gogusev J; Jaubert F; Oka T; Yoshino T
Clin Proteomics; 2015; 12(1):16. PubMed ID: 26097443
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.
Xiao Y; van Halteren AGS; Lei X; Borst J; Steenwijk E; de Wit T; Grabowska J; Voogd R; Kemps P; Picarsic J; van den Bos C; Borst J
Blood; 2020 Nov; 136(19):2188-2199. PubMed ID: 32750121
[TBL] [Abstract][Full Text] [Related]
9. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
10. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
Kobayashi M; Tojo A
Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
[TBL] [Abstract][Full Text] [Related]
12. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
Satoh T; Smith A; Sarde A; Lu HC; Mian S; Trouillet C; Mufti G; Emile JF; Fraternali F; Donadieu J; Geissmann F
PLoS One; 2012; 7(4):e33891. PubMed ID: 22506009
[TBL] [Abstract][Full Text] [Related]
13. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
15. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
17. Merkel cell polyomavirus DNA sequences in peripheral blood and tissues from patients with Langerhans cell histiocytosis.
Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
Hum Pathol; 2014 Jan; 45(1):119-26. PubMed ID: 24321520
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
19.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
20. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
